Screener
Mirum Pharmaceuticals, Inc. MIRM Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Amortized Cost | Unrealized Gain | Unrealized Loss | Estimated Fair Value |
|---|---|---|---|---|
| U.S. government bonds | 73,414 | 1 | (142) | 73,273 |
| Agency bonds | 16,500 | — | (69) | 16,431 |
| Commercial paper | 17,970 | — | — | 17,970 |
| Total cash equivalents and investments | $493,743 | $6 | $(472) | $493,277 |
| Classified as: | ||||
| Cash equivalents | $262,684 | |||
| Short-term investments | 107,563 | |||
| Long-term investments | 123,030 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s unrealized losses on investments (before tax)?
- Mirum Pharmaceuticals, Inc. (MIRM) reported unrealized losses on investments (before tax) of $472K in Q2 2026.
- What does unrealized losses on investments (before tax) mean?
- The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.
Ask your AI about Mirum Pharmaceuticals, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude